ORGAN DOSES AND EFFECTIVE DOSE FOR FIVE PET RADIOPHARMACEUTICALS

Martin Andersson; L Johansson; Sören Mattsson; David Minarik; Sigrid Leide-Svegborn

doi:10.1093/rpd/ncw033

ORGAN DOSES AND EFFECTIVE DOSE FOR FIVE PET RADIOPHARMACEUTICALS

Martin Andersson, L Johansson, Sören Mattsson, David Minarik, Sigrid Leide-Svegborn

Medical Radiation Physics, Malmö

Research output: Contribution to journal › Article › peer-review

Abstract

Diagnostic investigations with positron-emitting radiopharmaceuticals are dominated by (18)F-fluorodeoxyglucose ((18)F-FDG), but other radiopharmaceuticals are also commercially available or under development. Five of them, which are all clinically important, are (18)F-fluoride, (18)F-fluoroethyltyrosine ((18)F-FET), (18)F-deoxyfluorothymidine ((18)F-FLT), (18)F-fluorocholine ((18)F-choline) and (11)C-raclopride. To estimate the potential risk of stochastic effects (mainly lethal cancer) to a population, organ doses and effective dose values were updated for all five radiopharmaceuticals. Dose calculations were performed using the computer program IDAC2.0, which bases its calculations on the ICRP/ICRU adult reference voxel phantoms and the tissue weighting factors from ICRP publication 103. The biokinetic models were taken from ICRP publication 128. For organ doses, there are substantial changes. The only significant change in effective dose compared with previous estimations was a 46 % reduction for (18)F-fluoride. The estimated effective dose in mSv MBq(-1) was 1.5E-02 for (18)F-FET, 1.5E-02 for (18)F-FLT, 2.0E-02 for (18)F-choline, 9.0E-03 for (18)F-fluoride and 4.4E-03 for (11)C-raclopride.

Original language	English
Pages (from-to)	253-8
Journal	Radiation Protection Dosimetry
Volume	169
Issue number	1-4
Early online date	2016 Mar 13
DOIs	https://doi.org/10.1093/rpd/ncw033
Publication status	Published - 2016 Jun

Subject classification (UKÄ)

Pharmacology and Toxicology
Radiology, Nuclear Medicine and Medical Imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/rpd/ncw033

1 Doctoral Thesis (compilation)

Radiation dose to patients in diagnostic nuclear medicine. Implementation of improved anatomical and biokinetic models for assessment of organ absorbed dose and effective dose.
Andersson, M., 2017, Lund: Lund University: Faculty of Medicine. 62 p.
Research output: Thesis › Doctoral Thesis (compilation)

Open Access
File

Cite this

@article{38a1c1332c3c4e9ba910aab0d00a3412,

title = "ORGAN DOSES AND EFFECTIVE DOSE FOR FIVE PET RADIOPHARMACEUTICALS",

abstract = "Diagnostic investigations with positron-emitting radiopharmaceuticals are dominated by (18)F-fluorodeoxyglucose ((18)F-FDG), but other radiopharmaceuticals are also commercially available or under development. Five of them, which are all clinically important, are (18)F-fluoride, (18)F-fluoroethyltyrosine ((18)F-FET), (18)F-deoxyfluorothymidine ((18)F-FLT), (18)F-fluorocholine ((18)F-choline) and (11)C-raclopride. To estimate the potential risk of stochastic effects (mainly lethal cancer) to a population, organ doses and effective dose values were updated for all five radiopharmaceuticals. Dose calculations were performed using the computer program IDAC2.0, which bases its calculations on the ICRP/ICRU adult reference voxel phantoms and the tissue weighting factors from ICRP publication 103. The biokinetic models were taken from ICRP publication 128. For organ doses, there are substantial changes. The only significant change in effective dose compared with previous estimations was a 46 % reduction for (18)F-fluoride. The estimated effective dose in mSv MBq(-1) was 1.5E-02 for (18)F-FET, 1.5E-02 for (18)F-FLT, 2.0E-02 for (18)F-choline, 9.0E-03 for (18)F-fluoride and 4.4E-03 for (11)C-raclopride.",

author = "Martin Andersson and L Johansson and S{\"o}ren Mattsson and David Minarik and Sigrid Leide-Svegborn",

year = "2016",

month = jun,

doi = "10.1093/rpd/ncw033",

language = "English",

volume = "169",

pages = "253--8",

journal = "Radiation Protection Dosimetry",

issn = "1742-3406",

publisher = "Oxford University Press",

number = "1-4",

}

TY - JOUR

T1 - ORGAN DOSES AND EFFECTIVE DOSE FOR FIVE PET RADIOPHARMACEUTICALS

AU - Andersson, Martin

AU - Johansson, L

AU - Mattsson, Sören

AU - Minarik, David

AU - Leide-Svegborn, Sigrid

PY - 2016/6

Y1 - 2016/6

N2 - Diagnostic investigations with positron-emitting radiopharmaceuticals are dominated by (18)F-fluorodeoxyglucose ((18)F-FDG), but other radiopharmaceuticals are also commercially available or under development. Five of them, which are all clinically important, are (18)F-fluoride, (18)F-fluoroethyltyrosine ((18)F-FET), (18)F-deoxyfluorothymidine ((18)F-FLT), (18)F-fluorocholine ((18)F-choline) and (11)C-raclopride. To estimate the potential risk of stochastic effects (mainly lethal cancer) to a population, organ doses and effective dose values were updated for all five radiopharmaceuticals. Dose calculations were performed using the computer program IDAC2.0, which bases its calculations on the ICRP/ICRU adult reference voxel phantoms and the tissue weighting factors from ICRP publication 103. The biokinetic models were taken from ICRP publication 128. For organ doses, there are substantial changes. The only significant change in effective dose compared with previous estimations was a 46 % reduction for (18)F-fluoride. The estimated effective dose in mSv MBq(-1) was 1.5E-02 for (18)F-FET, 1.5E-02 for (18)F-FLT, 2.0E-02 for (18)F-choline, 9.0E-03 for (18)F-fluoride and 4.4E-03 for (11)C-raclopride.

AB - Diagnostic investigations with positron-emitting radiopharmaceuticals are dominated by (18)F-fluorodeoxyglucose ((18)F-FDG), but other radiopharmaceuticals are also commercially available or under development. Five of them, which are all clinically important, are (18)F-fluoride, (18)F-fluoroethyltyrosine ((18)F-FET), (18)F-deoxyfluorothymidine ((18)F-FLT), (18)F-fluorocholine ((18)F-choline) and (11)C-raclopride. To estimate the potential risk of stochastic effects (mainly lethal cancer) to a population, organ doses and effective dose values were updated for all five radiopharmaceuticals. Dose calculations were performed using the computer program IDAC2.0, which bases its calculations on the ICRP/ICRU adult reference voxel phantoms and the tissue weighting factors from ICRP publication 103. The biokinetic models were taken from ICRP publication 128. For organ doses, there are substantial changes. The only significant change in effective dose compared with previous estimations was a 46 % reduction for (18)F-fluoride. The estimated effective dose in mSv MBq(-1) was 1.5E-02 for (18)F-FET, 1.5E-02 for (18)F-FLT, 2.0E-02 for (18)F-choline, 9.0E-03 for (18)F-fluoride and 4.4E-03 for (11)C-raclopride.

U2 - 10.1093/rpd/ncw033

DO - 10.1093/rpd/ncw033

M3 - Article

C2 - 26977075

SN - 1742-3406

VL - 169

SP - 253

EP - 258

JO - Radiation Protection Dosimetry

JF - Radiation Protection Dosimetry

IS - 1-4

ER -

ORGAN DOSES AND EFFECTIVE DOSE FOR FIVE PET RADIOPHARMACEUTICALS

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Research output

Radiation dose to patients in diagnostic nuclear medicine. Implementation of improved anatomical and biokinetic models for assessment of organ absorbed dose and effective dose.

Cite this